CSL Limited provided earnings guidance for the fiscal year 2022. CSL's net profit after tax for fiscal year 2022 is anticipated to be in the range of approximately $2.15 billion to $2.25 billion at constant currency. This includes approximately $90 million to $110 million in transaction costs related to the agreement to acquire Vifor Pharma.